Squarepoint’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-140,637
| Closed | -$95.4K | – | 5148 |
|
|
2025
Q2 | $95.4K | Buy |
140,637
+13,197
| +10% | +$4.26K | ﹤0.01% | 4175 |
|
|
2025
Q1 | $47.2K | Buy |
127,440
+61,219
| +92% | +$33.8K | ﹤0.01% | 4349 |
|
|
2024
Q4 | $47.3K | Buy |
66,221
+9,575
| +17% | +$9.92K | ﹤0.01% | 4850 |
|
|
2024
Q3 | $63.4K | Buy |
+56,646
| New | +$63.4K | ﹤0.01% | 3953 |
|
|
2021
Q2 | – | Sell |
-102,282
| Closed | -$352K | – | 3786 |
|
|
2021
Q1 | $352K | Sell |
102,282
-67,148
| -40% | -$209K | ﹤0.01% | 2282 |
|
|
2020
Q4 | $427K | Buy |
169,430
+38,968
| +30% | +$84.9K | ﹤0.01% | 1926 |
|
|
2020
Q3 | $275K | Buy |
130,462
+117,373
| +897% | +$279K | ﹤0.01% | 1863 |
|
|
2020
Q2 | $29K | Buy |
+13,089
| New | +$33.6K | ﹤0.01% | 2142 |
|
|
2020
Q1 | – | Sell |
-73,442
| Closed | -$193K | – | 2646 |
|
|
2019
Q4 | $193K | Buy |
73,442
+11,055
| +18% | +$33K | ﹤0.01% | 2235 |
|
|
2019
Q3 | $225K | Sell |
62,387
-47,389
| -43% | -$168K | ﹤0.01% | 2033 |
|
|
2019
Q2 | $370K | Sell |
109,776
-110,176
| -50% | -$388K | ﹤0.01% | 1834 |
|
|
2019
Q1 | $600K | Buy |
219,952
+16,550
| +8% | +$54.2K | 0.01% | 1389 |
|
|
2018
Q4 | $565K | Buy |
203,402
+59,346
| +41% | +$194K | 0.01% | 1184 |
|
|
2018
Q3 | $594K | Buy |
144,056
+69,656
| +94% | +$316K | 0.01% | 1231 |
|
|
2018
Q2 | $386K | Buy |
74,400
+34,202
| +85% | +$208K | 0.01% | 1278 |
|
|
2018
Q1 | $220K | Buy |
40,198
+1,674
| +4% | +$11.8K | ﹤0.01% | 1458 |
|
|
2017
Q4 | $314K | Sell |
38,524
-7,476
| -16% | -$71.4K | 0.01% | 1470 |
|
|
2017
Q3 | $482K | Buy |
46,000
+34,600
| +304% | +$384K | 0.01% | 999 |
|
|
2017
Q2 | $126K | Buy |
+11,400
| New | +$106K | ﹤0.01% | 1381 |
|
|
2017
Q1 | – | Sell |
-11,238
| Closed | -$78K | – | 1961 |
|
|
2016
Q4 | $78K | Buy |
+11,238
| New | +$71.7K | ﹤0.01% | 1657 |
|
Squarepoint's ENZ Position: Q3 2025 in Review
Squarepoint sold out of Enzo Biochem, Inc. (ENZ) in Q3 2025, closing a stake of 140,637 shares — an estimated $95.4K sold.
Squarepoint first reported a position in ENZ in Q4 2016 and held it in 20 quarters. The position peaked at $600K in Q1 2019. 0 funds tracked by Wall St. Rank hold ENZ as of Q3 2025.
- Squarepoint reported no remaining Enzo Biochem, Inc. position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 140,637 Enzo Biochem, Inc. shares in Q3 2025, an estimated $95.4K.
- Squarepoint first reported a position in Enzo Biochem, Inc. in Q4 2016 and held it in 20 quarters.
- Squarepoint's Enzo Biochem, Inc. position peaked at $600K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.